Glenmark Pharmaceuticals said on Tuesday it has started clinical preliminaries in India of antiviral medication favipiravir, seen as a potential treatment for the coronavirus illness (Covid-19), for which it got endorsement from the nation's medication controller in April.

Mumbai-based Glenmark said in a BSE documenting the endorsement made it the first pharmaceutical organization in Quite a while to be given the gesture by the Drug Controller General of India to begin preliminaries on Covid-19 patients.

Favipiravir is fabricated under the brand name Avigan by Fujifilm Toyama Chemical Co Ltd, an auxiliary of Japan's Fujifilm Holdings Corporation, and endorsed for use as an enemy of influenza tranquilize in the nation in 2014.

Glenmark said clinical preliminaries have started and in excess of 10 driving government and private emergency clinics in India are being enlisted for the examination. It gauges the examination fruition by July or August this year.

The organization said it has effectively evolved API and the plans for the item through its in house innovative work group.

"A few wellbeing and clinical specialists, both in and outside of Glenmark, are anxious to see the impact that Favipiravir has on COVID-19 cases. We accept the examination results will be critical as there is at present no powerful treatment for the infection," Dr Monika Tandon, VP and head of clinical turn of events, said in a BSE documenting.

"The information we get from these preliminaries will point us a more clear way with respect to COVID-19 treatment and the executives," Tandon included.

India's count of Covid-19 remained at 70,756 on Tuesday morning with 2293 fatalities the nation over, as per the wellbeing service's Covid-19 dashboard.

The Phase 3 clinical preliminaries come after a Chinese authority told journalists in April that a functioning element of the medication had been viable, with no conspicuous symptoms, in helping patients of the coronavirus illness recoup.

Drugmakers over the world have been racing to build up a treatment or antibody for the quick spreading coronavirus that has influenced in excess of 4,000,000 individuals and slaughtered 286,330 over the world and assaulted money related markets.